Clinical Trial Update: Efficacy and Safety of Pasireotide LAR (Long-acting Release) in Japanese Patients With Acromegaly or Pituitary Gigantism [Phase 2]

View source ↗

Summary

Phase 2 trial assessing efficacy and safety of pasireotide LAR in Japanese patients with acromegaly or pituitary gigantism has been completed with results poste…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acromegaly
• Pituitary Gigantism

Drugs mentioned

• Pasireotide LAR (pasireotide)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: Acromegaly, Pituitary Gigantism | Phase 2 | Status: COMPLETED | Results posted: 2019-09-16